Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice: Robbins LLP Urges Shareholders to Contact the Firm for Information Regarding Their Rights SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs...

Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice: Robbins LLP Urges Shareholders to Contact the Firm for Information Regarding Their Rights SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs...

Y-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Lead Plaintiff Deadline in Class Action Against Y-mAbs Therapeutics, Inc. SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs...

Y-mAbs Therapeutics, Inc. (YMAB) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Y-mAbs Therapeutics, Inc. SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs...